Telephone
61.3.9545.5940
Address
700 Swanston Street Level 7 Carlton, Victoria (VIC) 3053
Description
4DMedical Ltd. is a software technology company, which commercializes four-dimensional lung imaging platform called XV Technology. It develops pipeline products that may assist physicians to more effectively diagnose and manage patients with lung disease, which includes XV ventilation analysis, ventilation perfusion, contrast free pulmonary angiography, small animal ventilator, and preclinical scanner. The company was founded by Andreas Fouras in December 2012 and is headquartered in Carlton, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.29 - 1.27
Trade Value (12mth)
AU$133,847.00
1 week
-1.55%
1 month
109.89%
YTD
141.77%
1 year
122.09%
All time high
2.98
EPS 3 yr Growth
26.400%
EBITDA Margin
%
Operating Cashflow
-$23m
Free Cash Flow Return
-32.30%
ROIC
-44.80%
Interest Coverage
-142.90
Quick Ratio
4.60
Shares on Issue (Fully Dilluted)
306m
HALO Sector
Technology
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.01
Date | Announcements |
---|---|
31 October 23 |
Quarterly Activity Report and Appendix 4C for Q1 FY2024
×
Quarterly Activity Report and Appendix 4C for Q1 FY2024 |
31 May 23 |
Change in substantial holding
×
Change in substantial holding |
31 May 23 |
Change in substantial holding
×
Change in substantial holding |
31 May 23 |
Change in substantial holding
×
Change in substantial holding |
31 July 23 |
Quarterly Activity Report and Appendix 4C for Q4 FY2023
×
Quarterly Activity Report and Appendix 4C for Q4 FY2023 |
31 January 23 |
Quarterly Activity Report and Appendix 4C for Q2 FY2023
×
Quarterly Activity Report and Appendix 4C for Q2 FY2023 |
31 January 22 |
Quarterly Activity Report and Appendix 4C for Q2 FY2022
×
Quarterly Activity Report and Appendix 4C for Q2 FY2022 |
31 August 22 |
Vanderblit 'burn pit' trial hits primary endpoint
×
Vanderblit 'burn pit' trial hits primary endpoint |
31 August 21 |
2021 Annual General Meeting
×
2021 Annual General Meeting |
30 September 22 |
2022 Annual Report
×
2022 Annual Report |
30 September 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
30 October 23 |
4DMedical enters contract with Integral Diagnostics
×
4DMedical enters contract with Integral Diagnostics |
30 November 23 |
4DMedical Webinar
×
4DMedical Webinar |
30 May 23 |
Application for quotation of securities - 4DX
×
Application for quotation of securities - 4DX |
29 November 23 |
4DMedical and Philips sign Memorandum of Understanding
×
4DMedical and Philips sign Memorandum of Understanding |
29 November 22 |
4DMedical receives $9.4m from MRFF
×
4DMedical receives $9.4m from MRFF |
29 May 23 |
4DMedical completes oversubscribed $25m SPP
×
4DMedical completes oversubscribed $25m SPP |
29 May 23 |
Update - Proposed issue of securities - 4DX
×
Update - Proposed issue of securities - 4DX |
29 August 23 |
Annual Report and Appendix 4E
×
Annual Report and Appendix 4E |
29 August 23 |
FY2023 Full Year Results
×
FY2023 Full Year Results |
29 August 23 |
Corporate Governance Statement
×
Corporate Governance Statement |
29 August 23 |
Appendix 4G
×
Appendix 4G |
29 August 23 |
Notice of AGM Date
×
Notice of AGM Date |
29 April 22 |
Quarterly Activity Report and Appendix 4C for Q3 FY2022
×
Quarterly Activity Report and Appendix 4C for Q3 FY2022 |
28 September 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
28 September 21 |
2021 Notice of Annual General Meeting
×
2021 Notice of Annual General Meeting |
28 October 22 |
Quarterly Activity Report - Clarification
×
Quarterly Activity Report - Clarification |
28 October 21 |
2021 Annual General Meeting presentation
×
2021 Annual General Meeting presentation |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.